Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 279

Results For "development"

2905 News Found

SPI Pharma partners Azelis Americas
Supply Chain | August 07, 2021

SPI Pharma partners Azelis Americas

In the agreement, Marcor, an Azelis Americas company, will distribute the SPI Pharma product lines in the United States, and Azelis Canada Pharma Division will be responsible for the Canadian marketplace


Strides to acquire US manufacturing facility of Endo for $24 mn
News | August 06, 2021

Strides to acquire US manufacturing facility of Endo for $24 mn

The proposed acquisition will further bolster Strides US presence through acquisition of a multi dosage facility in the US.


Mark W. Womack is the new CEO of Stelis Biopharma
Biotech | August 06, 2021

Mark W. Womack is the new CEO of Stelis Biopharma

He will be stationed at the company HQ in Bengaluru, India


Govt augments PSEs and Bharat Biotech to ramp up Covaxin production
Policy | August 06, 2021

Govt augments PSEs and Bharat Biotech to ramp up Covaxin production

CDSCO to fast-track trials and approval for COVID19 vaccine


Scientists from BRICS work on genomic sequencing of Covid-19
Drug Approval | August 06, 2021

Scientists from BRICS work on genomic sequencing of Covid-19

Whole-genome sequencing to identify genetic mutation; epidemiological studies to help assess the distribution and mathematical modelling to forecast spread


Covaxin receives approval from Hungary
Biotech | August 05, 2021

Covaxin receives approval from Hungary

More countries recognise Covaxin


Clarivate  acquires Bioinfogate
Digitisation | August 05, 2021

Clarivate acquires Bioinfogate

Reinforcing position as a premier provider of end-to-end research intelligence solutions for Life Sciences


Glenmark signs agreement with SaNOtize to manufacture NONS
News | August 02, 2021

Glenmark signs agreement with SaNOtize to manufacture NONS

The Phase III clinical trial for NONS is expected to be completed by Q4 2021.


Granules India earmarks Rs 400 crore as Capex for FY 22
News | August 02, 2021

Granules India earmarks Rs 400 crore as Capex for FY 22

The company has an outlay of Rs 120-140 crore as R & D expense for FY 22


Takeda and Frazier Healthcare Partners collaborates for Norovirus vaccine candidate
Biotech | August 02, 2021

Takeda and Frazier Healthcare Partners collaborates for Norovirus vaccine candidate

Takeda Will Focus its Efforts on Dengue, Zika and Pandemic vaccines